Orexo AB (QX) News - ORXOY

Orexo's "Out the Monster" campaign wins a Gold Lions Health Award at the Cannes Lions Festival PR Newswire MORRISTOWN, N.J., June 25...

Orexo US launches new 8.6/2.1 mg ZUBSOLV® (buprenorphine/naloxone) sublingual tablet CIII: 8.6/2.1mg Offers additional option for physicians and...

Orexo Features Positive Results from the ISTART Study at the 2014 AAAP Meeting Data presented from largest combination buprenorphine/naloxone...

Orexo Launches ZUBSOLV Patient Assistance Program Helping eligible opioid dependent patients in need PR Newswire MORRISTOWN, N.J., Oct. 7, 2014...

Thu, Nov 21, 2013 - Orexo AB (ORXOY: OTCQX International) released a Company Presentation called Jefferies Global Healthcare Conf. 2013. To watch...

Orexo AB Begins Trading on OTCQX® PR Newswire NEW YORK, Nov. 13, 2013 NEW YORK, Nov. 13, 2013 /PRNewswire/ --OTC Markets Group Inc. (OTCQX:...

/C O R R E C T I O N -- Orexo U.S./ PR Newswire NEW YORK, Sept. 16, 2013 In the news release, Zubsolv® Now Available in the U.S. for the...

Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence Zubsolv is a new, advanced formulation treatment option for...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF...